Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02991196 · ClinicalTrials.gov registry record · Phase 1
Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
A Phase 1 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02991196 is a Phase 1 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 4 participants.
The verdict
NCT02991196, a Phase 1 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This trial is being performed in two parts: Dose Escalation and Dose Expansion. The primary objective for the Dose Escalation part is to determine the safety and tolerability at different doses of DS-8273a administered in combination with nivolumab and to identify the dose combination for the Dose Expansion cohort in subjects with mismatch repair (MMR)-proficient advanced colorectal cancer. The primary objectives for the Dose Expansion part are: * To further evaluate the safety and tolerability of DS-8273a administered at the selected dose in combination with nivolumab in subjects with MMR-proficient advanced colorectal cancer * To evaluate preliminary anti-tumor activity of DS-8273a plus nivolumab administered at the selected dose in subjects with MMR-proficient advanced colorectal cancer
Interventions
- DRUG DS-8273a + nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-12-01 |
| Est. Completion | 2017-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02991196
The ClinicalTrials.gov registry entry for NCT02991196 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DS-8273a + nivolumab is the first listed.
NCT02991196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02991196 about?
NCT02991196 is a clinical study titled "Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer". This trial is being performed in two parts: Dose Escalation and Dose Expansion. The primary objective for the Dose Escalation part is to determine the safety and tolerability at different doses of DS-8273a administered in combination with nivolumab and to identify the dose combination for the Dose ...
What is the current status of trial NCT02991196?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2016-12-01. Estimated completion is 2017-09-22.
What interventions are being tested in trial NCT02991196?
The interventions under investigation include: DS-8273a + nivolumab (DRUG).
Who is sponsoring clinical trial NCT02991196?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.